Duvall Diantha
- SEC CIK
- 0001696784
No open-market purchases or sales filed in the past year.
Current role at each company
- CRIS Curis IncCFOas of Jul 9, 2026
- GNCA Genocea Biosciences, Inc.CHIEF FINANCIAL OFFICERas of Jun 3, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Duvall Diantha as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
GNCA Genocea Biosciences, Inc.
CHIEF FINANCIAL OFFICER4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 (view filing)4:13 PM ET | Jun 2 | 1 day | Duvall DianthaCHIEF FINANCIAL OFFICER | SSale | −1.35K | $0.06 | −$81.3 | −1.8%75.4K after | |
| May 26, 2022 (view filing)4:11 PM ET | May 26 | Same day | Duvall DianthaCHIEF FINANCIAL OFFICER | SSale | −24.4K | $0.0765 | −$1.87K | −24.1%76.7K after | |
| Apr 5, 2022 (view filing) | Apr 4 | 1 day | Duvall DianthaCHIEF FINANCIAL OFFICER | SSale | −963 | $1.25 | −$1.20K | −1.0%91.8K after | |
| Mar 17, 2022 (view filing) | Mar 16 | 1 day | Duvall DianthaCHIEF FINANCIAL OFFICER | SSale | −2.87K | $1.10 | −$3.16K | −3.0%92.7K after |